Design Of Theranostic Nanoparticles For Medical Imaging And Lung Diseases Treatment

Universities and Institutes of France
September 29, 2023
Offerd Salary:Negotiation
Working address:N/A
Contract Type:Other
Working Time:Full time
Working type:N/A
Ref info:N/A

26 Aug 2023

Job Information


LAGEP - Université de Lyon

Research Field


Biological sciences » Biology

Biological sciences » Biological engineering

Researcher Profile

Recognised Researcher (R2)

Leading Researcher (R4)

First Stage Researcher (R1)

Established Researcher (R3)



Application Deadline

29 Sep 2023 - 22:00 (UTC)

Type of Contract


Job Status


Offer Starting Date

1 Jan 2024

Is the job funded through the EU Research Framework Programme?

Not funded by an EU programme

Is the Job related to staff position within a Research Infrastructure?


Offer Description

Lung pathologies are still challenging to diagnose and treat, despite advancements. Computed tomography (CT) is now the most effective clinical imaging method, yet it has a number of drawbacks. Spectral photon counting Scanner (SPCCT) is a new imaging modality with advantages over CT and has demonstrated its interest for lung pathologies. However, new contrast agents must be formulated in order to fully use the capabilities of SPCCT and improve lungs imaging. In addition to the need for better monitoring of lung diseases, better therapy is also required. Indeed, the administration of drugs in the lungs faces the problem of crossing different physiological barriers that limit the delivery of therapeutic actives to the target areas in sufficient doses while limiting the adverse effects.

Nanosystems are of diverse interest for pulmonary drug delivery. They can improve drug stability and solubility, lead to targeting and controlled and sustained release, protect pulmonary clearance mechanisms and improve drug delivery. The goal of this project is to develop a nanoplatform for simultaneous efficient SPCCT imaging contrast and drug delivery. The combination of contrast agents with therapeutic agents would allow the quantification of the delivered dose of the active agent, the study of its distribution in the lungs and the monitoring of the effectiveness of the treatments.

The major part of the PhD will consist on the formulation of nanoparticles. After formulation, the physicochemical properties will be studied (size, drug encapsulation and release, stability, interactions with biomolecules, etc.). Various analytical technics will be used in collaboration with ICSM (CEA, France). In vitro toxicity of formulations will also be evaluated on cells models of interest. In vitro and in vivo imaging efficiency will be evaluated in collaboration with cardiovascular radiologist (CREATIS lab, Lyon) on small animals. The PhD student will be trained for in vitro and in vivo work if necessary.

Funding category: Autre financement public Financement déjà acquis. PHD Country: France


Specific Requirements

Experience in labwork. A previous experience in research an academic lab is mandatory.

Skills and knowledge in chemistry, formulation for health applications, physicochemical analysis.

Interest in transdisciplinary subjects.

Motivated, curious, autonomous.

The beginning of the contract can be decided between the candidate and supervisors (dontract can start between november 2023 and august 2024).

Additional Information Work Location(s)

Number of offers available



LAGEP - Université de Lyon




Where to apply


https: // www.


From this employer

Recent blogs

Recent news